default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Samsung Bioepis, C-Bridge Capital to develop biosimilars in China

Lee Han-soo  Published 2019.02.11  11:23  Updated 2019.02.11 11:50

공유
default_news_ad2

Samsung Bioepis said Monday that it has signed a licensing agreement with C-Bridge Capital, a Chinese venture fund company.

Under the accord, C-Bridge will establish a new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis across a number of areas, including clinical development, regulatory registration and commercialization on Samsung Bioepis’ three biosimilars -- SB11 (original: Lucentis), SB12 (original: Soliris), and SB3 (original: Herceptin) -- in China.

Samsung Bioepis will receive an upfront payment, as well as royalties on sales. The two companies did not disclose any additional financial details.

“We want to play an important role in widening access to high-quality healthcare for patients throughout China,” Samsung Bioepis CEO Ko Han-sung said. “C-Bridge is the right partner for this mission as evidenced in its exceptional track record of successfully turning portfolio companies like AffaMed Therapeutics into leading biopharmaceutical companies in China and beyond.”

The agreement comes at a time when Samsung Bioepis is expanding its biosimilar business in China.

In January, the company signed a licensing agreement with 3SBio, a Chinese biotechnology firm, for multiple biosimilar candidates from Samsung Bioepis, including SB8 (original: Avastin).

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch